Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation
CONCLUSION: For Chinese patients, early introduction and reaching the target CsA concentration within four weeks after allo-HSCT have a positive effect on preventing GvHD, especially in the fourth week after HSCT. Compared to the Western population, the target CsA concentration is lower and the time required to reach the target (within 4 weeks) is longer in the Chinese population (274.75 ng/mL).PMID:37975575 | DOI:10.1080/16078454.2023.2275893 (Source: Hematology)
Source: Hematology - November 17, 2023 Category: Hematology Authors: Qingqing Fan Xiang Hui Xiang Li Qian Li Dihong Yang Yongqing Wang Source Type: research
Thrombotic events and prophylactic anticoagulation in pediatric patients with COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The incidence of VTE in children with COVID-19 is low, and prophylaxis based on ISTH standards is reasonable. Low-molecular-weight heparin (LMWH) for VTE prevention has a high level of safety. However, more high-quality studies are needed to understand the impact of anticoagulant therapy on VTE incidence in pediatric patients with COVID-19.PMID:37961978 | DOI:10.1080/16078454.2023.2275912 (Source: Hematology)
Source: Hematology - November 14, 2023 Category: Hematology Authors: Di Xie Xiaoming Xue Wenxiao Qiao Jinyun Wang Lihong Meng Zhang Ye Dian Li Yaoqin Sun Source Type: research
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar
Hematology. 2023 Dec;28(1):2280872. doi: 10.1080/16078454.2023.2280872. Epub 2023 Nov 14.ABSTRACTThrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality. The mechanisms of post-HSCT thrombocytopenia are multifactorial and complex. There are no clear consensus and guidelines for managing thrombocytopenia post-HSCT. Recently, there has been promising use of thrombopoietin receptor agonists (TPO-RAs), particularly eltrombopag and romiplostim, as treatments for post-HSCT thrombocytopenia. Notably, that...
Source: Hematology - November 14, 2023 Category: Hematology Authors: Abdulrahman F Al-Mashdali Amaal Gulied Mohammed M Bakr Mohamed A Yassin Source Type: research
Thrombotic events and prophylactic anticoagulation in pediatric patients with COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The incidence of VTE in children with COVID-19 is low, and prophylaxis based on ISTH standards is reasonable. Low-molecular-weight heparin (LMWH) for VTE prevention has a high level of safety. However, more high-quality studies are needed to understand the impact of anticoagulant therapy on VTE incidence in pediatric patients with COVID-19.PMID:37961978 | DOI:10.1080/16078454.2023.2275912 (Source: Hematology)
Source: Hematology - November 14, 2023 Category: Hematology Authors: Di Xie Xiaoming Xue Wenxiao Qiao Jinyun Wang Lihong Meng Zhang Ye Dian Li Yaoqin Sun Source Type: research
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar
Hematology. 2023 Dec;28(1):2280872. doi: 10.1080/16078454.2023.2280872. Epub 2023 Nov 14.ABSTRACTThrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality. The mechanisms of post-HSCT thrombocytopenia are multifactorial and complex. There are no clear consensus and guidelines for managing thrombocytopenia post-HSCT. Recently, there has been promising use of thrombopoietin receptor agonists (TPO-RAs), particularly eltrombopag and romiplostim, as treatments for post-HSCT thrombocytopenia. Notably, that...
Source: Hematology - November 14, 2023 Category: Hematology Authors: Abdulrahman F Al-Mashdali Amaal Gulied Mohammed M Bakr Mohamed A Yassin Source Type: research
Thrombotic events and prophylactic anticoagulation in pediatric patients with COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The incidence of VTE in children with COVID-19 is low, and prophylaxis based on ISTH standards is reasonable. Low-molecular-weight heparin (LMWH) for VTE prevention has a high level of safety. However, more high-quality studies are needed to understand the impact of anticoagulant therapy on VTE incidence in pediatric patients with COVID-19.PMID:37961978 | DOI:10.1080/16078454.2023.2275912 (Source: Hematology)
Source: Hematology - November 14, 2023 Category: Hematology Authors: Di Xie Xiaoming Xue Wenxiao Qiao Jinyun Wang Lihong Meng Zhang Ye Dian Li Yaoqin Sun Source Type: research
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar
Hematology. 2023 Dec;28(1):2280872. doi: 10.1080/16078454.2023.2280872. Epub 2023 Nov 14.ABSTRACTThrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality. The mechanisms of post-HSCT thrombocytopenia are multifactorial and complex. There are no clear consensus and guidelines for managing thrombocytopenia post-HSCT. Recently, there has been promising use of thrombopoietin receptor agonists (TPO-RAs), particularly eltrombopag and romiplostim, as treatments for post-HSCT thrombocytopenia. Notably, that...
Source: Hematology - November 14, 2023 Category: Hematology Authors: Abdulrahman F Al-Mashdali Amaal Gulied Mohammed M Bakr Mohamed A Yassin Source Type: research
Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients
Conclusion The MPN-10 score did not predict survival outcomes among Thai MPN patients. Higher MPN-10 was associated with more transfusion. Thai MPN patients reported lower MPN-10 compared to western population especially PV and ET.PMID:37942783 | DOI:10.1080/16078454.2023.2280731 (Source: Hematology)
Source: Hematology - November 9, 2023 Category: Hematology Authors: Naritsara Cherdchoo Chantana Polprasert Ponlapat Rojnuckarin Sunisa Kongkiatkamon Source Type: research
